APTURE LA-to-CS shunting showed sustained improvements in symptoms, quality of life, and functional capacity in HF patients over 3 years, outperforming MAGGIC predictions.
Does APTURE LA-to-CS shunting improve safety, symptoms, and clinical outcomes in patients with HF and LVEF >40%?
In an early feasibility study, LA-to-CS shunting appeared safe and was associated with sustained symptomatic improvement and better-than-predicted survival at 3 years in patients with HF and LVEF >40%.
Tasa de eventos absoluta: 0% vs 0%
In patients with HF and LVEF >40%, the APTURE LA-to-CS shunting confirmed an acceptable safety profile with stable right heart parameters and sustained improvements in symptoms, quality of life, and functional capacity at 3 years. Observed survival and HFH were superior to MAGGIC predictions.
Fioretti et al. (Fri,) informaron un otro. El shunt APTURE LA-to-CS mostró mejoras sostenidas en los síntomas, calidad de vida y capacidad funcional en pacientes con IC durante 3 años, superando las predicciones de MAGGIC.